194 related articles for article (PubMed ID: 38061987)
41. Special properties of cholinesterases in the cerebral cortex of Alzheimer's disease.
Geula C; Mesulam M
Brain Res; 1989 Sep; 498(1):185-9. PubMed ID: 2790472
[TBL] [Abstract][Full Text] [Related]
42. Potent Acetylcholinesterase Inhibitors: Potential Drugs for Alzheimer's Disease.
Akıncıoğlu H; Gülçin İ
Mini Rev Med Chem; 2020; 20(8):703-715. PubMed ID: 31902355
[TBL] [Abstract][Full Text] [Related]
43. Multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease: design, synthesis, biochemical evaluation, ADMET, molecular modeling, and QSAR analysis of novel donepezil-pyridyl hybrids.
Bautista-Aguilera OM; Esteban G; Chioua M; Nikolic K; Agbaba D; Moraleda I; Iriepa I; Soriano E; Samadi A; Unzeta M; Marco-Contelles J
Drug Des Devel Ther; 2014; 8():1893-910. PubMed ID: 25378907
[TBL] [Abstract][Full Text] [Related]
44. Coumarins as cholinesterase inhibitors: A review.
de Souza LG; Rennã MN; Figueroa-Villar JD
Chem Biol Interact; 2016 Jul; 254():11-23. PubMed ID: 27174134
[TBL] [Abstract][Full Text] [Related]
45. Inhibition of cholinesterase and monoamine oxidase-B activity by Tacrine-Homoisoflavonoid hybrids.
Sun Y; Chen J; Chen X; Huang L; Li X
Bioorg Med Chem; 2013 Dec; 21(23):7406-17. PubMed ID: 24128814
[TBL] [Abstract][Full Text] [Related]
46. Observation of the Elevation of Cholinesterase Activity in Brain Glioma by a Near-Infrared Emission Chemsensor.
Ma Y; Gao W; Ma S; Liu Y; Lin W
Anal Chem; 2020 Oct; 92(19):13405-13410. PubMed ID: 32864956
[TBL] [Abstract][Full Text] [Related]
47. Potentially procholinergic effects of medications commonly used in older adults.
Rockwood K; Walsh R; Martin E; Darvesh S
Am J Geriatr Pharmacother; 2011 Feb; 9(1):80-7. PubMed ID: 21459311
[TBL] [Abstract][Full Text] [Related]
48. Species- and concentration-dependent differences of acetyl- and butyrylcholinesterase sensitivity to physostigmine and neostigmine.
Bitzinger DI; Gruber M; Tümmler S; Michels B; Bundscherer A; Hopf S; Trabold B; Graf BM; Zausig YA
Neuropharmacology; 2016 Oct; 109():1-6. PubMed ID: 26772968
[TBL] [Abstract][Full Text] [Related]
49. The ratio of acetylcholinesterase to butyrylcholinesterase influences the specificity of assays for each enzyme in human brain.
Huff FJ; Reiter CT; Rand JB
J Neural Transm; 1989; 75(2):129-34. PubMed ID: 2918305
[TBL] [Abstract][Full Text] [Related]
50. Kinetics and molecular docking studies of loganin, morroniside and 7-O-galloyl-D-sedoheptulose derived from Corni fructus as cholinesterase and β-secretase 1 inhibitors.
Bhakta HK; Park CH; Yokozawa T; Min BS; Jung HA; Choi JS
Arch Pharm Res; 2016 Jun; 39(6):794-805. PubMed ID: 27106028
[TBL] [Abstract][Full Text] [Related]
51. The kinetic and molecular docking analysis of interactions between three V-type nerve agents and four human cholinesterases.
Li K; Liu Y; Liu Y; Li Q; Guo L; Xie J
Chem Biol Interact; 2023 Feb; 372():110369. PubMed ID: 36708975
[TBL] [Abstract][Full Text] [Related]
52. Brain cholinesterases: I. The clinico-histopathological and biochemical basis of Alzheimer's disease.
Shen ZX
Med Hypotheses; 2004; 63(2):285-97. PubMed ID: 15236793
[TBL] [Abstract][Full Text] [Related]
53. Comparative Kinetics of Acetyl- and Butyryl-Cholinesterase Inhibition by Green Tea Catechins|Relevance to the Symptomatic Treatment of Alzheimer's Disease.
Okello EJ; Mather J
Nutrients; 2020 Apr; 12(4):. PubMed ID: 32326457
[TBL] [Abstract][Full Text] [Related]
54. Design, Synthesis and Biological Evaluation of New Cycloalkyl Fused Quinolines Tethered to Isatin Schiff Bases as Cholinesterase Inhibitors.
Macha B; Kulkarni R; Garige AK; Palabindala R; Akkinepally R; Garlapati A
Comb Chem High Throughput Screen; 2022; 25(1):167-186. PubMed ID: 33308120
[TBL] [Abstract][Full Text] [Related]
55. Further SAR studies on natural template based neuroprotective molecules for the treatment of Alzheimer's disease.
Singh YP; Shankar G; Jahan S; Singh G; Kumar N; Barik A; Upadhyay P; Singh L; Kamble K; Singh GK; Tiwari S; Garg P; Gupta S; Modi G
Bioorg Med Chem; 2021 Sep; 46():116385. PubMed ID: 34481338
[TBL] [Abstract][Full Text] [Related]
56. Ultrasound-Assisted Synthesis of Piperidinyl-Quinoline Acylhydrazones as New Anti-Alzheimer's Agents: Assessment of Cholinesterase Inhibitory Profile, Molecular Docking Analysis, and Drug-like Properties.
Munir R; Zaib S; Zia-Ur-Rehman M; Hussain N; Chaudhry F; Younas MT; Zahra FT; Tajammul Z; Javid N; Dera AA; Ogaly HA; Khan I
Molecules; 2023 Feb; 28(5):. PubMed ID: 36903376
[TBL] [Abstract][Full Text] [Related]
57. TV 3326 for Alzheimer's dementia: a novel multimodal ChE and MAO inhibitors to mitigate Alzheimer's-like neuropathology.
Uddin MS; Kabir MT; Rahman MM; Mathew B; Shah MA; Ashraf GM
J Pharm Pharmacol; 2020 Aug; 72(8):1001-1012. PubMed ID: 32149402
[TBL] [Abstract][Full Text] [Related]
58. Inhibitory activities of major anthraquinones and other constituents from Cassia obtusifolia against β-secretase and cholinesterases.
Jung HA; Ali MY; Jung HJ; Jeong HO; Chung HY; Choi JS
J Ethnopharmacol; 2016 Sep; 191():152-160. PubMed ID: 27321278
[TBL] [Abstract][Full Text] [Related]
59. Synthesis and biological activity of derivatives of tetrahydroacridine as acetylcholinesterase inhibitors.
Szymański P; Markowicz M; Mikiciuk-Olasik E
Bioorg Chem; 2011 Aug; 39(4):138-42. PubMed ID: 21621811
[TBL] [Abstract][Full Text] [Related]
60. Bis-Amiridines as Acetylcholinesterase and Butyrylcholinesterase Inhibitors:
Makhaeva GF; Kovaleva NV; Boltneva NP; Rudakova EV; Lushchekina SV; Astakhova TY; Serkov IV; Proshin AN; Radchenko EV; Palyulin VA; Korabecny J; Soukup O; Bachurin SO; Richardson RJ
Molecules; 2022 Feb; 27(3):. PubMed ID: 35164325
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
